Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed the day trading at $42.87 down -8.79% from the previous closing price of $47.00. On the day, 1727233 shares were traded.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.61. In the meantime, Its Debt-to-Equity ratio is 3.39 whereas as Long-Term Debt/Eq ratio is at 3.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 08, 2023, initiated with a Overweight rating and assigned the stock a target price of $72.
Evercore ISI Upgraded its In-line to Outperform on June 06, 2023, whereas the target price for the stock was revised from $60 to $80.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Kassberg Thomas Richard sold 11,509 shares for $49.93 per share. The transaction valued at 574,644 led to the insider holds 252,823 shares of the business.
Fust Matthew K sold 12,195 shares of RARE for $620,443 on Mar 07 ’24. The Director now owns 14,860 shares after completing the transaction at $50.88 per share. On Mar 01 ’24, another insider, Harris Erik, who serves as the EVP & Chief Commercial Officer of the company, sold 4,768 shares for $53.76 each. As a result, the insider received 256,328 and left with 67,163 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.13 while its Price-to-Book (P/B) ratio in mrq is 12.81.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $54.98, while it has fallen to a 52-week low of $31.52.
Shares Statistics:
A total of 82.31M shares are outstanding, with a floating share count of 77.02M. Insiders hold about 6.45% of the company’s shares, while institutions hold 104.20% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from Ferrari N.V. analysts. The consensus estimate for the next quarter is $42.87, with high estimates of $119.18 and low estimates of $0.48.
Analysts are recommending an EPS of between $Real Estate and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
